公司概述
Jazz Pharmaceuticals plc is engaged in the identification, development, and commercialization of pharmaceutical products across the United States, Europe, and international markets. The company operates within the Healthcare sector and specifically functions in the Biotechnology industry, a domain characterized by high research and development costs and significant regulatory hurdles. Jazz maintains a substantial scale with a market capitalization of $12.20B, an annual revenue of $4.27B, and an workforce comprising 2890 employees. These valuation and revenue figures indicate that Jazz Pharmaceuticals plc holds a significant position within the biopharmaceutical landscape, possessing the capitalization to sustain operations and invest in product pipelines while generating multi-billion dollar sales streams.
财务健康
Jazz Pharmaceuticals plc reported a trailing twelve-month revenue of $4.27B alongside a net income of -$356,148,000 and an EBITDA of $1.71B. The substantial gap between the positive revenue and negative net income reveals a cost structure where operating expenses, likely driven by research and development or sales and marketing activities, exceed the gross profits generated from sales. Despite the net loss, the company generated $1.35B in free cash flow, which provides critical financial flexibility to fund ongoing operations, service debt obligations, and pursue strategic acquisitions without relying on external equity financing. The company's profitability metrics show a gross margin of 91.7%, indicating high pricing power and low cost of goods sold typical of pharmaceutical manufacturing, contrasted by an operating margin of 27.1% and a profit margin of -8.3% that reflects the heavy investment phase of the business. The balance sheet presents a leveraged profile with total cash of $2.44B against total debt of $5.43B and a debt-to-equity ratio of 125.67, suggesting a reliance on leverage which increases financial risk during periods of rising interest rates. However, the current ratio stands at 1.86, indicating that the company holds sufficient current assets to cover its short-term liabilities with a comfortable buffer. Return on equity is -8.5% and return on assets is 5.4%, metrics that collectively reveal management is currently generating returns on assets but failing to deliver positive returns on shareholders' equity due to the bottom-line losses.
估值评估
The valuation metrics display a trailing P/E ratio of N/A and a forward P/E of 7.92, implying that the market expects earnings to recover from the current negative levels to reach profitability in the coming periods. The price-to-book ratio is 2.82, which indicates that the market values the company at a significant premium over its tangible book value, likely reflecting the intangible value of its intellectual property and patent portfolios. Alternative valuation measures include a price-to-sales ratio of 2.86 and an EV/EBITDA of 8.86, suggesting that the company is valued relative to its cash flow generation potential rather than current earnings, a common practice for biotechnology firms in growth phases. The stock has traded between a 52-week low of $95.49 and a 52-week high of $200.24, providing a historical range to contextualize current price action relative to recent volatility. The beta value of 0.23 indicates that the stock exhibits low price volatility relative to the broader market, moving significantly less than the S&P 500 during periods of market turbulence.
Growth & Income
Jazz Pharmaceuticals plc has demonstrated robust expansion with revenue growth of 10.1% year-over-year and earnings growth of 3.2% year-over-year. The earnings growth rate is substantially slower than the revenue growth rate, which implies that while top-line sales are expanding, the company is still managing high fixed costs that prevent the immediate conversion of revenue into net profit. As a non-dividend payer, the company does not distribute a dividend yield or has a payout ratio of 0.0%, indicating that the firm prioritizes reinvesting all available earnings into research and development and commercialization efforts rather than distributing cash to shareholders. The overall growth and income profile is characterized by rapid top-line expansion supported by strong free cash flow conversion, yet tempered by the absence of current profitability and dividend distributions, positioning the asset as a growth-oriented biopharmaceutical investment.